Business Wire

MD-GET-REAL-HEALTH

21.9.2021 15:02:14 CEST | Business Wire | Press release

Share
Get Real Health Announces Further International Expansion to Bring Patient Engagement Tools Into The Netherlands

Get Real Health, a member of the CPSI (NASDAQ: CPSI) family of companies and a provider of comprehensive patient engagement tools, has expanded its international presence through an implementation in the region of Achterhoek, Netherlands, together with local partners MIJNPGO and WeDoTrust.

This implementation is meant to support the region’s ambition to become the healthiest region in the Netherlands by 2030. To that end, the project will have timed implementations and deployments aimed at improving healthcare across all demographics.

The Achterhoek solution is based on Get Real Health’s existing platform, and is customized for the region’s needs and called “MIJNPGO.” This customization effort includes ensuring compliance with Medmij, the technology standard across the Netherlands, which requires the secure exchange of data between care providers and patients. The initial pilot served a select cohort of care organizations including Sensire, the largest elderly care organization in the region. An expanded roll-out will utilize feedback and aim at improving the user experience over time.

“We are thrilled to participate in this important initiative. Our platform perfectly aligns with the mission of Achterhoek with respect to improved healthcare delivery and patient care outcomes both today and into the future,” said Robin Wiener, president of Get Real Health.

“In the Dutch region of Achterhoek, we are constantly working on adding more professional applications of modern technology in healthcare, together with other healthcare organizations and partners,” said Maarten van Rixtel, chief executive officer of Sensire, the largest elderly care organization in the region. “With MIJNPGO, the patients gain more insight into their own health. In addition, patients can share information with healthcare workers or caregivers. MIJNPGO therefore gives patients much more control over their own care and treatment process. This creates equal discussions and certain decisions can be made jointly. For us, MIJNPGO is one of the fundamental bases of healthcare for the future. We are looking forward to the moment when MIJNPGO will be used by many patients.”

Following the initial launch of the pilot in 2020, Get Real Health expanded the release of the platform at the end of August 2021, along with a website design refresh and portal upgrade to improve patient outcomes, enhance health, and implement a more engaging platform to the overall user base.

Through similar deployments in Canada, New Zealand, the Middle East and the United Kingdom, Get Real Health has established itself as an international presence in the patient engagement arena. “We see patient engagement as a global issue, and we develop applications with that philosophy in mind,” explained Wiener. “Our platform is flexible and scalable to serve individuals worldwide.”

About Get Real Health

Get Real Health, a member of the CPSI family of companies, combines a world of new information from patients, devices and apps with existing clinical data to help individuals and healthcare professionals engage and empower each other. By giving providers and patients the information and tools that they need to work together, we help our customers meet their ever-changing patient engagement needs. Our suite of products helps deliver value-based care, improve outcomes, activate patients, and increase patient loyalty and satisfaction, all while meeting regulatory requirements. For more information, visit www.getrealhealth.com .

About WeDoTrust

WeDoTrust is a consultancy and audit company. They assist healthcare institutions, among other things, in drawing up a realistic digital change agenda based on their strategy and financial possibilities. In doing so, they take into account the strength of the organization, market demand and the (im)possibilities of technology.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “projects,” “targets,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the success of Get Real Health’s solutions in the region of Achterhoek, Netherlands, are forward-looking statements. We caution investors that any such forward-looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward-looking statements. Such factors may include: the ability of Get Real Health’s technology and tools to successfully provide patients with more control over their healthcare information and allow greater accessibility to clinical teams and health records; the ability of Get Real Health’s platform to comply with the Medmij technology standard; the impact of the ongoing COVID-19 pandemic and related economic disruptions which have materially affected CPSI’s revenue and could materially affect CPSI’s gross margin and income, as well as CPSI’s financial position and/or liquidity; actions to be taken by CPSI in response to the pandemic; the legal, regulatory and administrative developments that occur at the federal, state and local levels; changes in revenues due to declining hospital demand and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); CPSI’s potential inability to attract and retain qualified client service and support personnel, as well as the disruptive effect of sales force restructurings; exposure to numerous laws, regulations and other requirements through CPSI’s international business activities; potential failure to develop or enhance products in response to market demands, as well as undetected errors or problems in new products or enhancements; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of CPSI’s or its partners’ information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; dependence on licenses of rights, products and services from third parties; service interruptions resulting from loss of power and/or telecommunications capabilities; potential increased expenses related to labor or other expenditures; the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms or at all, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financial perspective; and other risk factors described from time to time in CPSI’s public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, CPSI’s most recent Annual Report on Form 10-K. We also caution investors that the forward-looking information described herein represents CPSI’s outlook only as of this date, and CPSI undertakes no obligation to update or revise any forward-looking statements to reflect events or development after the date of this press release.

Link:

ClickThru

Social Media:

https://www.facebook.com/GetRealHealth/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an

Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release

Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye